title: ÐÐ»Ð¸ÑÐ½Ð¸Ðµ Ð°Ð³Ð¾Ð½Ð¸ÑÑÐ¾Ð² ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² PPARb Ð¸ PPARg Ð½Ð° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð³ÐµÐ½Ð¾Ð² Ð³Ð»Ð¸Ð°Ð»ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð² Ð² Ð¼Ð¾Ð·Ð³Ðµ ÐºÑÑÑ Ð² Ð»Ð¸ÑÐ¸Ð¹-Ð¿Ð¸Ð»Ð¾ÐºÐ°ÑÐ¿Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð²Ð¸ÑÐ¾ÑÐ½Ð¾Ð¹ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ð¸
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: The effect of PPARÎ²/Î´ and PPARÎ³ receptor agonists on the expression of glial protein genes in the rat brain in the lithium-pilocarpine model of temporal lobe epilepsy
Creators: name: Ð Ð¾Ð³Ð¸Ð½ÑÐºÐ°Ñ, ÐÐ½Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ñ
Ð²Ð¸ÑÐ¾ÑÐ½Ð°Ñ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ñ
Ð»Ð¸ÑÐ¸Ð¹-Ð¿Ð¸Ð»Ð¾ÐºÐ°ÑÐ¿Ð¸Ð½Ð¾Ð²Ð°Ñ Ð¼Ð¾Ð´ÐµÐ»Ñ
Ð°ÑÑÑÐ¾Ð³Ð»Ð¸Ñ
Ð¼Ð¸ÐºÑÐ¾Ð³Ð»Ð¸Ñ
epilepsy
temporal epilepsy
lithium-pylocarpine model
astroglias
microglias

description: Ð Ð°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð°Ð³Ð¾Ð½Ð¸ÑÑÐ¾Ð² PPARÎ²/Î´ Ð¸ PPARÎ³ Ð½Ð° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð³ÐµÐ½Ð¾Ð² Ð°ÑÑÑÐ¾- Ð¸ Ð¼Ð¸ÐºÑÐ¾Ð³Ð»Ð¸Ð°Ð»ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð², Ð²Ð¾Ð²Ð»ÐµÑÐµÐ½Ð½ÑÑ Ð² ÑÐµÐ³ÑÐ»ÑÑÐ¸Ñ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¾Ð³ÐµÐ½ÐµÐ·Ð°, Ð² ÐºÐ»ÐµÑÐºÐ°Ñ Ð¼Ð¾Ð·Ð³Ð° ÐºÑÑÑ Ð² Ð»Ð¸ÑÐ¸Ð¹-Ð¿Ð¸Ð»Ð¾ÐºÐ°ÑÐ¿Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð²Ð¸ÑÐ¾ÑÐ½Ð¾Ð¹ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ð¸. Ð Ð°Ð±Ð¾ÑÐ° Ð²ÑÐ¿Ð¾Ð»Ð½ÐµÐ½Ð° Ð½Ð° Ð±Ð°Ð·Ðµ ÐÐ°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½ÑÑ Ð¼ÐµÑÐ°Ð½Ð¸Ð·Ð¼Ð¾Ð² Ð½ÐµÐ¹ÑÐ¾Ð½Ð½ÑÑ Ð²Ð·Ð°Ð¸Ð¼Ð¾Ð´ÐµÐ¹ÑÑÐ²Ð¸Ð¹ ÐÐ­Ð¤Ð Ð ÐÐ. Ð Ð°Ð±Ð¾ÑÐ° Ð²ÐºÐ»ÑÑÐ°Ð»Ð° Ð´Ð²Ðµ ÑÐµÑÐ¸Ð¸ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ¾Ð², Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð½ÑÑ Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð°Ð³Ð¾Ð½Ð¸ÑÑÐ° PPARÎ³ Ð¿Ð¸Ð¾Ð³Ð»Ð¸ÑÐ°Ð·Ð¾Ð½Ð° Ð¸ Ð°Ð³Ð¾Ð½Ð¸ÑÑÐ° PPARÎ²/Î´ GW0742 Ð½Ð° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð³ÐµÐ½Ð¾Ð² Ð¸Ð½ÑÐµÑÐµÑÐ° Ð² Ð»Ð¸ÑÐ¸Ð¹-Ð¿Ð¸Ð»Ð¾ÐºÐ°ÑÐ¿Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ð¸ Ð½Ð° ÑÑÐ¾Ð²Ð½Ðµ Ð¼Ð ÐÐ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÐÐ¢-ÐÐ¦Ð  Ð² ÑÐµÐ°Ð»ÑÐ½Ð¾Ð¼ Ð²ÑÐµÐ¼ÐµÐ½Ð¸. Ð Ð¿ÑÐ¾ÑÐµÑÑÐµ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¾Ð³ÐµÐ½ÐµÐ·Ð° Ð² Ð»Ð¸ÑÐ¸Ð¹-Ð¿Ð¸Ð»Ð¾ÐºÐ°ÑÐ¿Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð½Ð°Ð±Ð»ÑÐ´Ð°ÐµÑÑÑ ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð¸Ðµ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð² Ð¼Ð°ÑÐºÐµÑÐ¾Ð² Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ð¸ Ð°ÑÑÑÐ¾- (Gfap) Ð¸ Ð¼Ð¸ÐºÑÐ¾Ð³Ð»Ð¸Ð¸ (Aif1), ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑÐ° Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð°-1 (Il1rn), Ð¼Ð°ÑÐºÐµÑÐ¾Ð² Ð1 ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð° Ð°ÑÑÑÐ¾Ð³Ð»Ð¸Ð¸ (Lcn2), Ð1 ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð° (Nlrp3), Ð2 ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð° (S100a10), ÑÐ¾ÑÑÐ¾Ð²ÑÑ ÑÐ°ÐºÑÐ¾ÑÐ¾Ð², Ð° ÑÐ°ÐºÐ¶Ðµ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° Ð¼Ð°ÑÐºÐµÑÐ° Ð2 ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð° (Arg1). ÐÐ²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð°Ð³Ð¾Ð½Ð¸ÑÑÐ° PPARÎ³ Ð¿Ð¸Ð¾Ð³Ð»Ð¸ÑÐ°Ð·Ð¾Ð½Ð° Ð¸ Ð°Ð³Ð¾Ð½Ð¸ÑÑÐ° PPARÎ² GW0742 ÑÐ°ÑÑÐ¸ÑÐ½Ð¾ Ð±Ð»Ð¾ÐºÐ¸ÑÐ¾Ð²Ð°Ð»Ð¾ ÑÑÐ¸ Ð½Ð°ÑÑÑÐµÐ½Ð¸Ñ. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð´Ð°Ð½Ð½ÑÐµ ÑÐºÐ°Ð·ÑÐ²Ð°ÑÑ Ð½Ð° Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸ÑÐµÐ»ÑÐ½ÑÐµ ÑÐ²Ð¾Ð¹ÑÑÐ²Ð° Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð½ÑÑ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð².
description: The work is devoted to the study of the effect of PPARÎ²/Î´ and PPARÎ³ agonists on the expression of genes of astro- and microglial proteins involved in the regulation of epileptogenesis in rat brain cells in the lithium-pilocarpine model of temporal lobe epilepsy. The work was performed at the Laboratory of Molecular Mechanisms of Neuronal Interactions, IEFB RAS. The work included two series of experiments devoted to studying the effect of PPARÎ³ agonist pioglitazone and PPARÎ² agonist GW0742 on the expression of genes of interest in the lithium-pilocarpine model of epilepsy at the mRNA level by real-time RT-PCR. During epileptogenesis in the lithium-pilocarpine model, we observed an increase in gene expression of markers of astro- (Gfap) and microglia (Aif1) activation, interleukin-1 receptor antagonist (Il1rn), Ð°stroglia A1 phenotype markers (Lcn2), M1 phenotype (Nlrp3), A2 phenotype (S100a10), growth factors, and decreased gene expression of A2 phenotype marker (Arg1). Administration of the PPARÎ³ agonist pioglitazone and the PPARÎ² agonist GW0742 partially blocked these impairments. The data obtained indicate anti-inflammatory properties of the drugs used.